Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598247 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of PPX in Women With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00598247 is a Phase 1 study that has completed, run by University of Southern California. The registered enrollment target is 15 participants.
The verdict
NCT00598247, a Phase 1 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study uses the drug PPX (also called Xyotax and CT-2103) in women with advanced colorectal cancer. PPX is an experimental drug that has not been approved by the Food and Drug Administration (FDA). PPX has been shown in the laboratory and in studies in humans to cause some cancer cells to die and some tumors to shrink. Women in some studies with PPX have been shown to live longer than the men that receive the drug. Some studies in humans suggest that estrogen (a hormone found in women) may protect women from getting colorectal cancer and allow women that do get colorectal cancer to live longer than men that do. The purpose of this study is to see if women with colorectal cancer and a certain level of estrogen experience tumor shrinkage after they receive the drug PPX. This study will also study genes (genes are the cell's blueprint) in participant's tumors and in their blood. Several genes can affect how people's bodies react to the cancer drugs. We want to see if these predict response to the study drugs.
Interventions
- DRUG Paclitaxel Poliglumex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00598247
The ClinicalTrials.gov registry entry for NCT00598247 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel Poliglumex is the first listed.
NCT00598247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00598247 about?
NCT00598247 is a clinical study titled "A Pilot Study of PPX in Women With Metastatic Colorectal Cancer". This study uses the drug PPX (also called Xyotax and CT-2103) in women with advanced colorectal cancer. PPX is an experimental drug that has not been approved by the Food and Drug Administration (FDA). PPX has been shown in the laboratory and in studies in humans to cause some cancer cells to die an...
What is the current status of trial NCT00598247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-01. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00598247?
The interventions under investigation include: Paclitaxel Poliglumex (DRUG).
Who is sponsoring clinical trial NCT00598247?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.